Subcutaneous Amivantimab: Overcoming Treatment Barriers and Shaping Advanced NSCLC Strategies

Opinion
Video

Focusing on treatment practices for patients with advanced EGFR-mutant NSCLC, Martin Dietrich, MD, PhD, discusses how the availability of subcutaneous amivantamab can potentially address current treatment barriers.

Video content above is prompted by the following:

  • How may the availability of subcutaneous amivantamab:
    • Address current treatment barriers/challenges and expand treatment options for patients with advanced NSCLC?
    • Impact 1L and 2L treatment strategies and the future role of amivantamab?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
4 experts in this video
Related Content